Home > Insider Trading > Filing (0001209191-16-108923)

Filing Details

Accession Number:: 0001209191-16-108923
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-03-16 18:26:36
Reporting Period:: 2016-03-14

Filing Date:: 2016-03-16
Accepted Time:: 2016-03-16 18:26:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
949858	Oncogenex Pharmaceuticals Inc.	OGXI	In Vitro & In Vivo Diagnostic Substances (2835)	954343413

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1442675	Daniel Scott Cormack	400-1001 W. Broadway Vancouver A1 V6H 4B1	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-03-14	25,000	$0.00	136,942	No	4	M	Direct
Common Stock	Disposition	2016-03-15	12,033	$0.83	124,909	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit (RSU)	Disposition	2016-03-14	4,687	$0.00	4,687	$0.00
Common Stock	Restricted Stock Unit (RSU)	Disposition	2016-03-14	4,688	$0.00	4,688	$0.00
Common Stock	Restricted Stock Unit (RSU)	Disposition	2016-03-14	6,250	$0.00	6,250	$0.00
Common Stock	Restricted Stock Unit (RSU)	Disposition	2016-03-14	9,375	$0.00	9,375	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2016-03-14	300,000	$0.00	300,000	$0.85
Common Stock	Stock Option (right to buy)	Acquisiton	2016-03-14	135,000	$0.00	135,000	$0.85

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2016-04-13	No	4	M	Direct
4,687	2017-01-31	No	4	M	Direct
12,500	2018-04-13	No	4	M	Direct
28,125	2019-06-18	No	4	M	Direct
300,000	2026-03-14	No	4	A	Direct
135,000	2026-03-14	No	4	A	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	68,743	Indirect	By Spouse

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (right to buy)	$7.25	2016-05-12	4,130	4,130	Indirect
Common Stock	Stock Option (right to buy)	$14.20	2020-06-08	1,750	1,750	Indirect
Common Stock	Stock Option (right to buy)	$16.83	2021-01-03	28,820	28,820	Indirect
Common Stock	Stock Option (right to buy)	$13.00	2022-05-08	14,362	14,362	Indirect
Common Stock	Stock Option (right to buy)	$11.95	2023-03-12	20,000	20,000	Indirect
Common Stock	Restricted Stock Unit	$0.00	2017-01-31	2,500	2,500	Indirect
Common Stock	Stock Option (right to buy)	$11.79	2024-03-14	25,000	25,000	Indirect
Common Stock	Restricted Stock Unit (RSU)	$0.00	2018-04-13	6,250	6,250	Indirect
Common Stock	Restricted Stock Unit (right to buy)	$0.00		5,000	5,000	Indirect
Common Stock	Restricted Stock Unit (RSU)	$0.00		15,000	15,000	Indirect
Common Stock	Stock Option (right to buy)	$1.86	2025-05-19	37,500	37,500	Indirect
Common Stock	Restricted Stock Unit (RSU)	$0.00	2019-06-18	14,062	14,062	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2016-05-12	4,130	4,130	Indirect
2020-06-08	1,750	1,750	Indirect
2021-01-03	28,820	28,820	Indirect
2022-05-08	14,362	14,362	Indirect
2023-03-12	20,000	20,000	Indirect
2017-01-31	2,500	2,500	Indirect
2024-03-14	25,000	25,000	Indirect
2018-04-13	6,250	6,250	Indirect
	5,000	5,000	Indirect
	15,000	15,000	Indirect
2025-05-19	37,500	37,500	Indirect
2019-06-18	14,062	14,062	Indirect

Footnotes

Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest on the later of: (i) each anniversary of January 1, 2012; and (ii) the first day thereafter during which the issuer's trading window is open.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open.
Pursuant to the terms of the options, 50% of the total shares underlying the option vest on the achievement of certain milestones, and 50% vest in monthly installments over 24 months commencing one month from achievement of one of the milestones. The options will lapse in full if achievement of one of the milestones is not met on or before December 31, 2016.
The options were fully vested on May 12, 2010.
The options were fully vested on May 26, 2011.
The options were fully vested on January 3, 2015.
The options were fully vested on January 1, 2016.
The options vest in monthly installments over 48 months commencing one month from January 1, 2013.
The options vest in monthly installments over 48 months commencing one month from January 1, 2014.
Pursuant to the terms of the RSU, 100% of the total shares underlying the RSU vest on the later of (i) release of positive data from a clinical trial, and (ii) the first trading day thereafter on which the issuer's trading window is open.
The RSUs expire 30 days from the date they vest.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of June 12, 2014 and (ii) the first day thereafter during which the issuer's trading window is open.
The options vest in monthly installments over 48 months commencing one month from January 1, 2015.